The effects of lovastatin and simvastatin on the diurnal periodicity of plasma mevalonate concentrations in patients with heterozygous familial hypercholesterolemia

Atherosclerosis

Volumn 165, Issue 1, 2002, Pages 137-144

  Pappu, Anuradha S ^a   Illingworth, D Roger ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Cholesterol synthesis; Familial hypercholesterolemia; Lovastatin; Mevalonic acid; Simvastatin

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; MEVINOLIN; SIMVASTATIN;

ADULT; ARTICLE; BLOOD LEVEL; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENDER; HETEROZYGOSITY; HUMAN; LIPOGENESIS; NIGHT; PERIODICITY; PRIORITY JOURNAL; TIME;

ADULT; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CIRCADIAN RHYTHM; FEMALE; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LOVASTATIN; MEVALONIC ACID; MIDDLE AGED; PERIODICITY; PROBABILITY; PROSPECTIVE STUDIES; SAMPLING STUDIES; SIMVASTATIN; URINALYSIS;

EID: 0036841917     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(02)00192-2     Document Type: Article

References (37)

1. Simons K., Ikonen E. Functional rafts in cell membranes. Nature. 387:1997;569-572.
2. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature. 343:1990;425-430.
3. Pappu A.S., Illingworth D.R. Diurnal variations in the plasma concentrations of mevalonic acid in patients with abetalipoproteinaemia. Eur. J. Clin. Invest. 24:1994;698-702.
4. Parker T.S., McNamara D.J., Brown C.D., Kolb R., Ahrens E.H. Jr, Alberts A.W., Tobert J., Chen J., De Schepper P.J. Plasma mevalonate as a measure of cholesterol synthesis in man. J. Clin. Invest. 74:1984;795-804.
5. Parker T.S., McNamara D.J., Brown C., Garrigan O., Kolb R., Batwin H., Ahrens E.H. Jr. Mevalonic acid in human plasma: relationship of concentration and circadian rhythm to cholesterol synthesis rates in man. Proc. Natl. Acad. Sci. USA. 79:1982;3037-3041.
6. Miettinen T.A. Diurnal variation of cholesterol precursors squalene and methyl sterols in human plasma lipoproteins. J. Lipid Res. 23:1982;466-473.
7. Jones P.J., Schoeller D.A. Evidence for diurnal periodicity in human cholesterol synthesis. J. Lipid Res. 31:1990;667-673.
8. Jones P.J., Pappu A.S., Illingworth D.R., Leitch C.A. Correspondence between plasma mevalonic acid levels and deuterium uptake in measuring human cholesterol synthesis. Eur. J. Clin. Invest. 22:1992;609-613.
9. Brown M.S., Goldstein J.L. Familial hypercholesterolemia: genetic, biochemical and pathophysiologic considerations. Adv. Intern. Med. 20:1975;273-296.
10. Kelley M.J., Story J.A. Effect of type of diet and feeding status on modulation of hepatic HMG-CoA reductase in rats. Lipids. 20:1985;53-55.
11. Illingworth D.R., Tobert J.A. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin. Ther. 16:1994;366-385.
12. Vaughan C.J., Murphy M.B., Buckley B.M. Statins do more than just lower cholesterol. Lancet. 348:1996;1079-1082.
13. Hagemenas F.C., Pappu A.S., Illingworth D.R. The effects of simvastatin on plasma lipoproteins and cholesterol homeostasis in patients with heterozygous familial hypercholesterolaemia. Eur. J. Clin. Invest. 20:1990;150-157.
14. Packard C.J., Shepherd J. Current concepts in the treatment of familial hypercholesterolaemia. Curr. Opin. Lipidol. 6:1995;57-61.
15. Illingworth D.R. Comparative efficacy of one versus twice daily mevinolin in the therapy of familial hypercholesterolemia. Clin. Pharmacol. Ther. 40:1986;338-343.
16. Popjak G., Boehm G., Parker T.S., Edmond J., Edwards P.A., Fogelman A.M. Determination of mevalonate in blood plasma in man and rat. Mevalonate 'tolerance' tests in man. J. Lipid Res. 20:1979;716-728.
17. Illingworth D.R., Pappu A.S., Gregg R.E. Increased urinary mevalonic acid excretion in patients with abetalipoproteinemia and homozygous hypobetalipoproteinemia. Atherosclerosis. 76:1989;21-27.
18. National heart, Lung and Blood Institute. Lipid Research Clinical Manual 1. Bethesda, MD Department of Health. 1974:Publication No. 75-628.74.
19. SPSS Inc. SPSS Statistics version 9; Chicago, IL.
20. Illingworth D.R., Bacon S., Pappu A.S., Sexton G.J. Comparative hypolipidemic effects of lovastatin and simvastatin in patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 96:1992;53-64.
21. Nozaki S., Nakagawa T., Nakata A., Yamashita S., Kameda-Takemura K., Nakamura T., Keno Y., Tokunaga K., Matsuzawa Y. Effects of pravastatin on plasma and urinary mevalonate concentrations in subjects with familial hypercholesterolaemia: a comparison of morning and evening administration. Eur. J. Clin. Pharmacol. 49:1996;361-364.
22. Pappu A.S., Illingworth D.R., Bacon S. Reduction in plasma low density lipoprotein cholesterol and urinary mevalonic acid by lovastatin in patients with heterozygous familial hypercholesterolemia. Metabolism. 38:1989;542-549.
23. Kopito R.R., Weinstock S.B., Freed L.E., Murray D.M., Brunengraber H. Metabolism of plasma mevalonate in rats and humans. J. Lipid Res. 23:1982;577-583.
24. Jones P.J. Use of deuterated water for measurement of short-term cholesterol synthesis in humans. Can. J. Physiol. Pharmacol. 68:1990;955-959.
25. Cilla D.D. Jr, Gibson D.M., Whitfield L.R., Sedman A.J. Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J. Clin. Pharmacol. 36:1996;604-609.
26. Lennernas H., Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin. Pharmacokinet. 32:1997;403-425.
27. Faix D., Neese P., Kletke C., Wolden S., Ceser D., Coutlangus M., Shakelton C.H., Hellerstein M.K. Quantification of menstrual and diurnal periodicities in rates of cholesterol and fat synthesis in humans. J. Lipid Res. 34:1993;2063-2075.
28. Shapiro D.J., Rodwell V.W. Regulation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase and cholesterol synthesis. J. Biol. Chem. 246:1971;3210-3216.
29. Gibbons G.F., Pullinger C.R. Diurnal variations in the effects of an unsaturated-fat-containing diet on fatty acid and cholesterol synthesis in rat hepatocytes. Biochem. J. 239:1986;617-623.
30. Jones P.J., Pappu A.S., Hatcher L., Li Z.C., Illingworth D.R., Connor W.E. Dietary cholesterol feeding suppresses human cholesterol synthesis measured by deuterium incorporation and urinary mevalonic acid levels. Arterioscler. Thromb. Vasc. Biol. 16:1996;1222-1228.
31. Jenkins D.J., Khan A., Jenkins A.L., Illingworth R., Pappu A.S., Wolever T.M., Vuksan V., Buckley G., Rao A.V., Cunnane S.C. Effect of nibbling versus gorging on cardiovascular risk factors: serum uric acid and blood lipids. Metabolism. 44:1995;549-555.
32. Cella L.K., Van Cauter E., Schoeller D.A. Effect of meal timing on diurnal rhythm of human cholesterol synthesis. Am. J. Physiol. 269:1995;E878-E883.
33. Mann J. Meal frequency and plasma lipids and lipoproteins. Br. J. Nutr. 1:(77 Suppl):1997;S83-S90.
34. Cullinane E.M., Yurgalevitch S.M., Saritelli A.L., Herbert P.N., Thompson P.D. Variations in plasma volume affect total and low-density lipoprotein cholesterol concentrations during the menstrual cycle. Metab. Clin. Exp. 44:1995;965-971.
35. Zilversmit D.B. A proposal linking atherogenesis to the interaction of endothelial lipoprotein lipase with triglyceride-rich lipoproteins. Circ. Res. 33:1973;633-638.
36. Van Lenten B.J., Fogelman A.M., Jackson R.L., Shapiro S., Haberland M.E., Edwards P.A. Receptor-mediated uptake of remnant lipoproteins by cholesterol-loaded human monocyte-macrophages. J. Biol. Chem. 260:1985;8783-8788.
37. Wade D.P., Knight B.L., Soutar A.K. Detection of the low-density-lipoprotein receptor with biotin-low-density lipoprotein. A rapid new method for ligand blotting. Biochem. J. 229:1985;785-790.